TY - JOUR
T1 - Current and future management of chronic spontaneous urticaria and chronic inducible urticaria
AU - Do, Toan T.
AU - Canty, Ethan A.
AU - Joshi, Shyam R.
N1 - Publisher Copyright:
Copyright © 2023, OceanSide Publications, Inc., U.S.A.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Background: Chronic urticaria (CU), characterized by ≥6 weeks of intense pruritus, remains a debilitating condition for patients. New and safe treatments are needed to manage CU recalcitrant to standard therapy. Objective: A review of the current literature of standard and novel therapeutics in the management of CU was conducted. Methods: A literature search via a medical literature data base and clinical trial data base was conducted to identify treatment options for CU and current clinical trials. Results: Second-generation antihistamines, omalizumab, and cyclosporine remain the most proven therapeutic options for CU. Dupilumab, mepolizumab, benralizumab, tezepelumab, and CDX-0159 are all undergoing clinical trials for CU. Although ligelizumab demonstrated initial promising results, a phase III study was discontinued due to a nonsuperior clinical impact compared with omalizumab. Conclusion: Novel therapies are needed for the treatment of recalcitrant CU. With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU.
AB - Background: Chronic urticaria (CU), characterized by ≥6 weeks of intense pruritus, remains a debilitating condition for patients. New and safe treatments are needed to manage CU recalcitrant to standard therapy. Objective: A review of the current literature of standard and novel therapeutics in the management of CU was conducted. Methods: A literature search via a medical literature data base and clinical trial data base was conducted to identify treatment options for CU and current clinical trials. Results: Second-generation antihistamines, omalizumab, and cyclosporine remain the most proven therapeutic options for CU. Dupilumab, mepolizumab, benralizumab, tezepelumab, and CDX-0159 are all undergoing clinical trials for CU. Although ligelizumab demonstrated initial promising results, a phase III study was discontinued due to a nonsuperior clinical impact compared with omalizumab. Conclusion: Novel therapies are needed for the treatment of recalcitrant CU. With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU.
UR - http://www.scopus.com/inward/record.url?scp=85145598272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145598272&partnerID=8YFLogxK
U2 - 10.2500/aap.2023.44.220093
DO - 10.2500/aap.2023.44.220093
M3 - Article
C2 - 36719690
AN - SCOPUS:85145598272
SN - 1088-5412
VL - 44
SP - 3
EP - 14
JO - Allergy and Asthma Proceedings
JF - Allergy and Asthma Proceedings
IS - 1
ER -